ArticleFrontiers in cardiovascular medicine2025
Analysis of the correlation between EAT thickness and prognosis in patients with heart failure with preserved ejection fraction.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epicardial adipose tissue as a determinant of heart failure prognosis: insights across ejection fraction phenotypes.Cardiovascular diabetology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the correlation between epicardial adipose tissue (EAT) thickness and prognosis in patients with heart failure with preserved ejection fraction. Method: A total of 156 patients diagnosed with heart failure with preserved ejection fraction (HFpEF) were selected as the observation group. Another 150 healthy persons undergoing physical examination were selected as the control group. According to the 1-year follow-up results of prognosis of HFpEF patients, they were further divided into a good prognosis group (112 cases) and a poor prognosis group (44 cases). Result: The EAT thickness, left ventricular mass index (LVMI), left atrial diameter (LAD), and left ventricular end-diastolic diameter (LVEDD) of HFpEF patients in the observation group were higher than those of the control group, and their LVEF was lower than that of the control group. EAT thickness was negatively correlated with LVEF, and EAT thickness was positively correlated with LVMI, LAD, and LVEDD. Hemoglobin and estimated renal glomeruli of the poor prognosis group were lower than those of the good prognosis group. The EAT thickness, blood lactate, and serum creatinine in the poor prognosis group were higher than those in the good prognosis group. Reduced hemoglobin, increased EAT thickness, and increased blood lactate were risk factors for poor prognosis in patients with HFpEF. The receiver operating characteristic analysis showed that the optimal EAT cutoff value was 5.65 mm (area under the curve = 0.892, 95% CI = 0.833-0.936), with 89.13% sensitivity and 88.39% specificity. For the Kaplan-Meier survival analysis, when performing the Conclusion: EAT thickness is inversely related to HFpEF severity and reflects left ventricular remodeling. EAT thickness may be a potentially useful non-invasive prognostic indicator of poorer outcomes in patients with HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.